Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanoFlu Phase 2 Dose and Formulation Confirmation in Older Adults
NCT03658629Phase 2Terminated
- Sponsor
- Novavax
- Start
- Sep 2018
- Primary completion
- Apr 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Influenza B virus B/Maryland/15/2016 recombinant hemagglutinin antigen in influenza (7 arms), sponsored by Novavax. Primary endpoints: Number of Subjects With Adverse Events, Hemagglutination Inhibition (HAI) Titers Specific for Vaccine Homologous A and B Influenza Strains Expressed as Geometric Mean Titer (GMT) at Day 28 and 1 more. Started Sep 2018; status: terminated.
02
Drugs
Influenza B virus B/Maryland/15/2016 recombinant hemagglutinin antigen
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03658629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03658629.